The tweet was deleted by the author.
But we saved everything 🙂.
PDS Biotechnology has announced the appointments of John Dawson, Deborah Ramsdell, and Bruce Wendel to its Board of Directors. The three executives bring extensive experience in the pharmaceutical sector.
The company highlighted these appointments as a move to strengthen its governance and strategic leadership as it advances its oncology programs.
View post on X Loading...
Earlier this year, PDS Biotechnology published Phase 2 trial results for its HPV16 immunotherapy and shifted its focus to PDS0301 in metastatic colorectal cancer, according to a company update. The firm is also scheduled to present new PDS0301 clinical data in advanced liver-related cancers at an upcoming virtual KOL event, as announced in previous disclosures. These recent developments align with the company’s initiatives to advance its oncology pipeline.